patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_406891 | REC_0006301 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 5.7 | 79 | female | 1 | 61 | 6.8 | 0 | pembrolizumab 200 mg q3w | 29.5 | false | MSS | 2026-03-15T05:35:58.401587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396656 | REC_0006302 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 4.5 | 70 | female | 2 | 10 | 5.8 | 6 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.401817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481461 | REC_0006303 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13.9 | 63 | male | 0 | 14 | 6.2 | 4 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:58.402057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619623 | REC_0006304 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8.1 | 77 | female | 2 | 39 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.402286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440227 | REC_0006305 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.8 | 81 | female | 3 | 13 | 5 | 3 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:58.402521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968123 | REC_0006306 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.5 | 86 | female | 1 | 10 | 4.1 | 6 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.402797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448328 | REC_0006307 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 16.2 | 75 | female | 2 | 17 | 7 | 0 | sotorasib 960 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:58.403032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482107 | REC_0006308 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 12.4 | 73 | female | 2 | 0 | 7 | 1 | osimertinib 80 mg daily | 22 | true | MSI-H | 2026-03-15T05:35:58.403263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732731 | REC_0006309 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 15 | 8.4 | 64 | female | 1 | 17 | 4.7 | 0 | alectinib 600 mg BID | 54 | false | MSS | 2026-03-15T05:35:58.403495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914080 | REC_0006310 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 13.3 | 68 | female | 0 | 19 | 6.4 | 1 | alectinib 600 mg BID | 21.9 | false | MSS | 2026-03-15T05:35:58.403726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247668 | REC_0006311 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.7 | 70 | female | 3 | 65 | 4.1 | 6 | pembrolizumab 200 mg q3w | 10 | true | MSS | 2026-03-15T05:35:58.403954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205304 | REC_0006312 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 4.1 | 77 | female | 2 | 70 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 24 | true | MSS | 2026-03-15T05:35:58.404210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813714 | REC_0006313 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 4.3 | 78 | female | 2 | 64 | 5 | 0 | carboplatin + paclitaxel + pembrolizumab | 45.3 | true | MSS | 2026-03-15T05:35:58.404443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115714 | REC_0006314 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15 | 70 | female | 1 | 7 | 4.8 | 6 | entrectinib 600 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:58.404675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504242 | REC_0006315 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.2 | 70 | female | 1 | 18 | 5.2 | 6 | alectinib 600 mg BID | 8.6 | true | MSS | 2026-03-15T05:35:58.404903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610520 | REC_0006316 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.1 | 75 | female | 1 | 5 | 6 | 8 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:58.405128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164536 | REC_0006317 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.6 | 64 | male | 0 | 19 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:58.405359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953476 | REC_0006318 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 14.5 | 73 | female | 1 | 4 | 4.4 | 1 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:58.405588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739473 | REC_0006319 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 8.7 | 52 | male | 0 | 86 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.2 | true | MSS | 2026-03-15T05:35:58.405869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324826 | REC_0006320 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 12 | 66 | female | 1 | 23 | 3.5 | 2 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:58.406102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335373 | REC_0006321 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.8 | 70 | female | 1 | 33 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:58.406331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907468 | REC_0006322 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 3 | 62 | female | 1 | 15 | 3.3 | 7 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:58.406563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360978 | REC_0006323 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.4 | 72 | male | 2 | 19 | 5.7 | 1 | osimertinib 80 mg daily | 26.1 | true | MSS | 2026-03-15T05:35:58.406798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157586 | REC_0006324 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 10.6 | 64 | female | 0 | 16 | 4 | 7 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.407031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560915 | REC_0006325 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 1.5 | 62 | male | 1 | 18 | 3.7 | 2 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:58.407261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571650 | REC_0006326 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.1 | 63 | male | 1 | 50 | 5 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:58.407492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494217 | REC_0006327 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.8 | 75 | female | 1 | 23 | 5 | 8 | osimertinib 80 mg daily | 4.7 | true | MSI-H | 2026-03-15T05:35:58.407728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767421 | REC_0006328 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 9.2 | 61 | female | 0 | 20 | 5.6 | 6 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:58.407958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438042 | REC_0006329 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 15.5 | 50 | male | 0 | 18 | 6.3 | 2 | sotorasib 960 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:58.408215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386080 | REC_0006330 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.1 | 67 | male | 0 | 11 | 8.6 | 6 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.408450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722498 | REC_0006331 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 11.9 | 61 | male | 1 | 18 | 4.6 | 6 | entrectinib 600 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:58.408684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215683 | REC_0006332 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 11.5 | 52 | female | 0 | 10 | 7.1 | 3 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:58.408961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638667 | REC_0006333 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13 | 61 | male | 0 | 18 | 5.8 | 4 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:58.409200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904578 | REC_0006334 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 6.4 | 67 | female | 1 | 27 | 6.5 | 1 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:58.409427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183552 | REC_0006335 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.4 | 64 | female | 0 | 22 | 4.4 | 9 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:58.409662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860804 | REC_0006336 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 9.9 | 70 | male | 1 | 26 | 3.1 | 7 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:58.409893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531435 | REC_0006337 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 9.9 | 61 | male | 1 | 53 | 5.4 | 1 | pembrolizumab 200 mg q3w | 28.8 | true | MSS | 2026-03-15T05:35:58.410125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188921 | REC_0006338 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 6.7 | 56 | female | 0 | 21 | 2.5 | 9 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.410357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425007 | REC_0006339 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.7 | 70 | female | 0 | 12 | 3.1 | 7 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.410589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638697 | REC_0006340 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 13.7 | 54 | male | 0 | 22 | 5.8 | 6 | pembrolizumab 200 mg q3w | 7.9 | true | MSS | 2026-03-15T05:35:58.410823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677386 | REC_0006341 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.1 | 79 | female | 2 | 13 | 3.9 | 5 | osimertinib 80 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:35:58.411055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773995 | REC_0006342 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 17.5 | 68 | female | 1 | 16 | 6.5 | 1 | alectinib 600 mg BID | 24.9 | true | MSS | 2026-03-15T05:35:58.411286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986345 | REC_0006343 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.6 | 71 | female | 1 | 20 | 5 | 7 | alectinib 600 mg BID | 9.8 | true | MSI-H | 2026-03-15T05:35:58.411519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556475 | REC_0006344 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 14.9 | 54 | male | 0 | 7 | 5.3 | 6 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.411752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812580 | REC_0006345 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.2 | 62 | male | 1 | 14 | 7.1 | 1 | osimertinib 80 mg daily | 27 | true | MSI-H | 2026-03-15T05:35:58.412031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685879 | REC_0006346 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.3 | 59 | male | 1 | 20 | 3.2 | 5 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:58.412304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410388 | REC_0006347 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.3 | 69 | female | 1 | 16 | 5.9 | 5 | osimertinib 80 mg daily | 6.1 | true | MSS | 2026-03-15T05:35:58.412546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378208 | REC_0006348 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 16.4 | 55 | female | 0 | 28 | 6.4 | 6 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:58.412797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129224 | REC_0006349 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.8 | 72 | female | 2 | 12 | 5 | 6 | alectinib 600 mg BID | 4.6 | false | MSS | 2026-03-15T05:35:58.413039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745090 | REC_0006350 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.3 | 66 | male | 0 | 9 | 5.9 | 6 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:58.413278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709697 | REC_0006351 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 13 | 64 | female | 1 | 12 | 6.3 | 2 | osimertinib 80 mg daily | 26.1 | true | MSI-H | 2026-03-15T05:35:58.413521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110327 | REC_0006352 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 11.7 | 69 | female | 1 | 12 | 5.3 | 1 | sotorasib 960 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:58.413756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546042 | REC_0006353 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 15.1 | 84 | female | 1 | 21 | 5.9 | 1 | osimertinib 80 mg daily | 22.3 | true | MSS | 2026-03-15T05:35:58.413988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625700 | REC_0006354 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.8 | 69 | female | 0 | 15 | 6.1 | 2 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:58.414221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615824 | REC_0006355 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 8.8 | 53 | female | 0 | 12 | 3.6 | 0 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:35:58.414451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903442 | REC_0006356 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.2 | 73 | male | 1 | 7 | 8.3 | 3 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.414687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640069 | REC_0006357 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.9 | 61 | female | 1 | 20 | 4.8 | 4 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.414918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259241 | REC_0006358 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 15.6 | 72 | female | 1 | 5 | 6.5 | 1 | sotorasib 960 mg daily | 16 | true | MSI-H | 2026-03-15T05:35:58.415247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312712 | REC_0006359 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 7.8 | 74 | female | 2 | 13 | 5 | 7 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.415480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521785 | REC_0006360 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.4 | 61 | male | 0 | 6 | 5.3 | 6 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:58.415716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110666 | REC_0006361 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.6 | 77 | female | 1 | 23 | 5.7 | 2 | sotorasib 960 mg daily | 25.9 | true | MSI-H | 2026-03-15T05:35:58.415948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957532 | REC_0006362 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.8 | 58 | female | 0 | 40 | 4.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:58.416294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995953 | REC_0006363 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 6.8 | 58 | male | 0 | 18 | 5.2 | 2 | osimertinib 80 mg daily | 26 | false | MSS | 2026-03-15T05:35:58.416536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437550 | REC_0006364 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.4 | 76 | female | 2 | 11 | 3.8 | 7 | sotorasib 960 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:58.416767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441519 | REC_0006365 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.8 | 76 | female | 2 | 8 | 6.2 | 3 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.417001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136110 | REC_0006366 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 32 | 12.7 | 65 | male | 1 | 9 | 7 | 0 | osimertinib 80 mg daily | 34.6 | false | MSS | 2026-03-15T05:35:58.417234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296701 | REC_0006367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.8 | 66 | female | 0 | 12 | 4.3 | 4 | osimertinib 80 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.417464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864667 | REC_0006368 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 16.9 | 60 | female | 0 | 10 | 8.5 | 7 | osimertinib 80 mg daily | 17.8 | true | MSS | 2026-03-15T05:35:58.417697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879278 | REC_0006369 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.3 | 65 | male | 1 | 67 | 4.8 | 6 | pembrolizumab 200 mg q3w | 14.7 | true | MSS | 2026-03-15T05:35:58.417928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625160 | REC_0006370 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.4 | 73 | female | 1 | 18 | 6.4 | 1 | alectinib 600 mg BID | 14.3 | true | MSI-H | 2026-03-15T05:35:58.418160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884758 | REC_0006371 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 9.1 | 63 | male | 1 | 13 | 5 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:58.418445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893577 | REC_0006372 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.2 | 63 | male | 1 | 29 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.418682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615458 | REC_0006373 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.6 | 68 | male | 1 | 52 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 20.1 | true | MSS | 2026-03-15T05:35:58.418914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651539 | REC_0006374 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 18.3 | 59 | male | 1 | 20 | 7.1 | 0 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.419149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763566 | REC_0006375 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.9 | 62 | female | 0 | 18 | 5.7 | 2 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:58.419388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719578 | REC_0006376 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 8.7 | 65 | female | 0 | 18 | 4.6 | 5 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:58.419619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428119 | REC_0006377 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.3 | 71 | female | 1 | 25 | 4.5 | 3 | sotorasib 960 mg daily | 9 | false | MSS | 2026-03-15T05:35:58.419852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868322 | REC_0006378 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.1 | 67 | female | 1 | 30 | 5.6 | 6 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:58.420111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378159 | REC_0006379 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.6 | 63 | female | 1 | 18 | 7 | 5 | sotorasib 960 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:58.420351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703238 | REC_0006380 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 18 | 64 | female | 0 | 17 | 3.8 | 2 | sotorasib 960 mg daily | 20 | false | MSS | 2026-03-15T05:35:58.420588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166860 | REC_0006381 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.4 | 51 | female | 0 | 10 | 6.8 | 6 | sotorasib 960 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.420815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249578 | REC_0006382 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 6.1 | 67 | female | 1 | 14 | 7.1 | 0 | pembrolizumab 200 mg q3w | 34.6 | false | MSS | 2026-03-15T05:35:58.421040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997800 | REC_0006383 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.4 | 62 | male | 1 | 13 | 5 | 1 | osimertinib 80 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:58.421277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915902 | REC_0006384 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.8 | 69 | male | 1 | 7 | 4.7 | 7 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:35:58.421558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708037 | REC_0006385 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 3.2 | 76 | female | 2 | 11 | 5.6 | 0 | entrectinib 600 mg daily | 20 | false | MSS | 2026-03-15T05:35:58.421788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917857 | REC_0006386 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 13.2 | 77 | male | 1 | 5 | 6.6 | 1 | sotorasib 960 mg daily | 32.4 | true | MSI-H | 2026-03-15T05:35:58.422021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775598 | REC_0006387 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.7 | 74 | female | 2 | 50 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.3 | true | MSS | 2026-03-15T05:35:58.422249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606275 | REC_0006388 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.3 | 55 | male | 1 | 18 | 5.1 | 1 | osimertinib 80 mg daily | 24.7 | false | MSI-H | 2026-03-15T05:35:58.422485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534537 | REC_0006389 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.4 | 75 | male | 0 | 9 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:35:58.422716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422548 | REC_0006390 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.2 | 63 | female | 1 | 16 | 4.4 | 7 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.422950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605414 | REC_0006391 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.4 | 68 | female | 0 | 9 | 4.2 | 5 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:58.423188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377407 | REC_0006392 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.5 | 62 | male | 0 | 28 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.3 | false | MSS | 2026-03-15T05:35:58.423420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914939 | REC_0006393 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 9.2 | 68 | female | 0 | 21 | 6.3 | 1 | osimertinib 80 mg daily | 21.6 | true | MSS | 2026-03-15T05:35:58.423652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573162 | REC_0006394 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8 | 53 | male | 0 | 47 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.4 | false | MSS | 2026-03-15T05:35:58.423879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425066 | REC_0006395 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.3 | 57 | male | 0 | 23 | 4.1 | 2 | entrectinib 600 mg daily | 24.7 | false | MSS | 2026-03-15T05:35:58.424167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745615 | REC_0006396 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 8.5 | 76 | female | 2 | 12 | 3.4 | 2 | sotorasib 960 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:58.424400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142251 | REC_0006397 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.1 | 68 | female | 1 | 8 | 5.7 | 5 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:58.424693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135593 | REC_0006398 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14.8 | 73 | female | 2 | 16 | 7.5 | 3 | entrectinib 600 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:58.424927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903127 | REC_0006399 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.2 | 58 | male | 0 | 14 | 6.7 | 2 | sotorasib 960 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:58.425168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404479 | REC_0006400 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 5 | 69 | female | 1 | 37 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.8 | true | MSS | 2026-03-15T05:35:58.425402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.